Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme-Reference-Cited by-同舟云学术

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

Published:2018-07-23 Issue:1 Volume:123 Page:98-105
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

De Giorgi Ugo¹^ORCID,Cartenì Giacomo²,Giannarelli Diana³,Basso Umberto⁴,Galli Luca⁵,Cortesi Enrico⁶,Caserta Claudia⁷,Pignata Sandro⁸,Sabbatini Roberto⁹,Bearz Alessandra¹⁰,Buti Sebastiano¹¹,Lo Re Giovanni¹²,Berruti Alfredo¹³,Bracarda Sergio¹⁴,Cognetti Francesco¹⁵,Rastelli Francesca¹⁶,Fornarini Giuseppe¹⁷,Porta Camillo¹⁸¹⁹,Turci Daniele²⁰,Sternberg Cora N.²¹^ORCID,Procopio Giuseppe²²,

Affiliation:

1. Department of Medical Oncology; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS; Meldola Italy

2. Department of Medical Oncology; Azienda Ospedaliero-Universitaria “A. Cardarelli”; Napoli Italy

3. Department of Statistics; Regina Elena National Cancer Institute - IRCCS; Rome Italy

4. Medical Oncology Unit 1; Department of Clinical and Experimental Oncology; Istituto Oncologico Veneto IOV - IRCCS; Padova Italy

5. Department of Medical Oncology; Azienda Ospedaliero-Universitaria Pisana Spedali Riuniti S. Chiara; Pisa Italy

6. Department of Medical Oncology; Policlinico Umberto I; Roma Italy

7. Department of Medical Oncology; Azienda Ospedaliero-Universitaria di Santa Maria; Terni Italy

8. Department of Uro-Gynaecological Oncology; Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”; Napoli Italy

9. Department of Oncology and Hematology; Azienda Ospedaliero-Universitaria Policlinico di Modena; Modena Italy

10. Department of Medical Oncology; Istituto Nazionale Tumori - IRCCS; Aviano Italy

11. Medical Oncology Unit; Azienda Ospedaliero-Universitaria di Parma; Parma Italy

12. Department of Medical Oncology; CRO Pordenone-S.Vito Oncology; CRO - IRCCS; Aviano Italy

13. Department of Medical Oncology; ASST Spedali Civili di Brescia; Brescia Italy

14. Department of Medical Oncology; Azienda USL 8; Arezzo Italy

15. Department of Medical Oncology; Regina Elena National Cancer Institute - IRCCS; Rome Italy

16. Department of Medical Oncology; Fermo Area Vasta 4; Fermo Italy

17. Department of Medical Oncology; Azienda Ospedaliero-Universitaria San Martino IST - IRCCS; Genova Italy

18. University of Pavia and IRCCS San Matteo University Hospital Foundation; Pavia Italy

19. IRCCS San Matteo University Hospital Foundation; Pavia Italy

20. Department of Medical Oncology; Ospedale Santa Maria delle Croci; Ravenna Italy

21. Department of Medical Oncology; San Camillo Forlanini Hospital; Roma Italy

22. Department of Medical Oncology; Istituto Nazionale Tumori - IRCCS; Milano Italy

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14461/fullpdf

Reference22 articles.

1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012

2. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma;Farolfi;Expert Opin Drug Metab Toxicol,2016

3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

4. Administration USFD FDA Expands Use of Immunotherapeutic to Kidney Cancer (2015) https://blog.aacr.org/fda-approval-nivolumab-kidney-cancer/

5. Agency EM New treatment for advanced form of kidney cancer (2016) http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/02/WC500202416.pdf

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of modern immunotherapy in combination treatment of patients with renal cancer and bone metastases;Cancer Urology;2024-08-15

2. Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study;ESMO Open;2024-07

3. Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC;Cancers;2024-06-20

4. Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models;Cancer Immunology, Immunotherapy;2024-06-04

5. Seguridad y eficacia del nivolumab para el tratamiento de pacientes con carcinoma de células renales metastásico e insuficiencia renal;Actas Urológicas Españolas;2024-05